BACKGROUND: There is a need to identify active new regimens in patients with advanced urothelial cancer. Pemetrexed and gemcitabine are active agents in advanced urothelial cancer. A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelial cancer who were previously untreated for metastatic disease. METHODS: Forty-six patients with advanced urothelial carcinoma received pemetrexed disodium 500 mg/m2 and gemcitabine 1000 mg/m2 intravenously on Day 1, with gemcitabine repeated on Day 8. Cycles were repeated every 3 weeks for a maximum of 6 cycles. RESULTS: Two patients attained a complete response, and 12 patients attained a partial response for an overall response rate of 31.8% (90% confidence interval, 20.4%-45.2%). The median time to disease progression was 5.8 months, and the median overall survival was 13.4 months. Thirty-three patients (75%) experienced grade>or=3 neutropenia, and 5 patients (11%) had febrile neutropenia. There were 2 therapy-related deaths. CONCLUSIONS: The combination of pemetrexed and gemcitabine had moderate antitumor activity in previously untreated patients with advanced urothelial cancer at the expense of significant myelosuppression. Copyright (c) 2008 American Cancer Society.
BACKGROUND: There is a need to identify active new regimens in patients with advanced urothelial cancer. Pemetrexed and gemcitabine are active agents in advanced urothelial cancer. A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelial cancer who were previously untreated for metastatic disease. METHODS: Forty-six patients with advanced urothelial carcinoma received pemetrexed disodium 500 mg/m2 and gemcitabine 1000 mg/m2 intravenously on Day 1, with gemcitabine repeated on Day 8. Cycles were repeated every 3 weeks for a maximum of 6 cycles. RESULTS: Two patients attained a complete response, and 12 patients attained a partial response for an overall response rate of 31.8% (90% confidence interval, 20.4%-45.2%). The median time to disease progression was 5.8 months, and the median overall survival was 13.4 months. Thirty-three patients (75%) experienced grade>or=3 neutropenia, and 5 patients (11%) had febrile neutropenia. There were 2 therapy-related deaths. CONCLUSIONS: The combination of pemetrexed and gemcitabine had moderate antitumor activity in previously untreated patients with advanced urothelial cancer at the expense of significant myelosuppression. Copyright (c) 2008 American Cancer Society.
Authors: Clet Niyikiza; Sharyn D Baker; David E Seitz; Jackie M Walling; Katrina Nelson; James J Rusthoven; Sally P Stabler; Paolo Paoletti; A Hilary Calvert; Robert H Allen Journal: Mol Cancer Ther Date: 2002-05 Impact factor: 6.261
Authors: Matthew D Galsky; Svetlana Mironov; Alexia Iasonos; Joseph Scattergood; Mary G Boyle; Dean F Bajorin Journal: Invest New Drugs Date: 2006-12-05 Impact factor: 3.850
Authors: C Shih; V J Chen; L S Gossett; S B Gates; W C MacKellar; L L Habeck; K A Shackelford; L G Mendelsohn; D J Soose; V F Patel; S L Andis; J R Bewley; E A Rayl; B A Moroson; G P Beardsley; W Kohler; M Ratnam; R M Schultz Journal: Cancer Res Date: 1997-03-15 Impact factor: 12.701
Authors: H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte Journal: J Clin Oncol Date: 2000-09 Impact factor: 44.544
Authors: A A Adjei; C Erlichman; J A Sloan; J M Reid; H C Pitot; R M Goldberg; P Peethambaram; P Atherton; L J Hanson; S R Alberts; J Jett Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: David J Vaughn; Judith Manola; Robert Dreicer; William See; Ralph Levitt; George Wilding Journal: Cancer Date: 2002-09-01 Impact factor: 6.860
Authors: A Bamias; G Aravantinos; C Deliveliotis; D Bafaloukos; C Kalofonos; N Xiros; A Zervas; D Mitropoulos; E Samantas; D Pectasides; P Papakostas; D Gika; C Kourousis; A Koutras; C Papadimitriou; C Bamias; P Kosmidis; M A Dimopoulos Journal: J Clin Oncol Date: 2003-12-09 Impact factor: 44.544
Authors: B J Roth; R Dreicer; L H Einhorn; D Neuberg; D H Johnson; J L Smith; G R Hudes; S M Schultz; P J Loehrer Journal: J Clin Oncol Date: 1994-11 Impact factor: 44.544
Authors: Christopher M Tully; Andrea B Apolo; Emily C Zabor; Ashley M Regazzi; Irina Ostrovnaya; Helena F Furberg; Jonathan E Rosenberg; Dean F Bajorin Journal: Cancer Date: 2015-11-30 Impact factor: 6.860
Authors: Sumanta Kumar Pal; Yulan Ingrid Lin; Bertram Yuh; Kara DeWalt; Austin Kazarian; Nicholas Vogelzang; Rebecca A Nelson Journal: PLoS One Date: 2015-08-26 Impact factor: 3.240